Burgoyne, P., Hayes, A. J., Cooper, R. S., Le Brocq, M. L., Hansell, C. A.H., Campbell, J. D.M. and Graham, G. J. (2022) CCR7+ dendritic cells sorted by binding of CCL19 show enhanced Ag-presenting capacity and antitumor potency. Journal of Leukocyte Biology, 111(6), pp. 1243-1251. (doi: 10.1002/JLB.5AB0720-446RR) (PMID:34780080)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
257791.pdf - Published Version Available under License Creative Commons Attribution. 1MB |
Abstract
Dendritic cell therapy has been a promising addition to the current armory of therapeutic options in cancer for more than 20 years but has not yet achieved breakthrough success. To successfully initiate immunity, dendritic cells have to enter the lymph nodes. However, experience to date of therapeutic dendritic cell administration indicates that this is frequently an extremely inefficient process. The major regulator of dendritic cell migration to the lymph nodes is the chemokine receptor CCR7 and in vitro generated dendritic cells typically display heterogeneous expression of this receptor. Here we demonstrate that positive selection for the dendritic cell subpopulation expressing CCR7, using a chemically-synthesized ligand:CCL19, enriches for cells with enhanced lymph node migration and Ag presentation competence as well as a chemokine expression profile indicative of improved interactions with T cells. This enhanced lymph node homing capacity of enriched CCR7+ cells is seen in comparison to a population of unsorted dendritic cells containing an equivalent number of CCR7+ dendritic cells. Importantly, this indicates that separating the CCR7+ dendritic cells from the CCR7− cells, rather than simple CCL19 exposure, is required to affect the enhanced lymph node migration of the CCR7+ cells. In models of both subcutaneous and metastatic melanoma, we demonstrate that the dendritic cells sorted for CCR7 expression trigger enhanced CD8 T-cell driven antitumor immune responses which correlate with reduced tumor burden and increased survival. Finally, we demonstrate that this approach is directly translatable to human dendritic cell therapy using the same reagents coupled with clinical-grade flow-cytometric sorting.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Burgoyne, Paul and Le Brocq, Dr Michelle and Hansell, Dr Chris and Campbell, Dr John and Hayes, Mr Alan and Graham, Professor Gerard |
| Authors: | Burgoyne, P., Hayes, A. J., Cooper, R. S., Le Brocq, M. L., Hansell, C. A.H., Campbell, J. D.M., and Graham, G. J. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
| Research Centre: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology |
| Journal Name: | Journal of Leukocyte Biology |
| Publisher: | Wiley |
| ISSN: | 0741-5400 |
| ISSN (Online): | 1938-3673 |
| Published Online: | 15 November 2021 |
| Copyright Holders: | Copyright © 2021 The Authors |
| First Published: | First published in Journal of Leukocyte Biology 111:1243-1251 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information